Bio & health systems

Setup

Computational design cut candidate generation cost by roughly an order of magnitude and shortened the design-make-test loop from months to weeks. The pipeline filled fast and the platform narrative was clean: more shots on goal, cheaper.

What happened

Clinical validation cost and cycle time did not move at all. Trial recruitment, site contracting and regulatory review are governed by human and institutional throughput, not compute, so the bottleneck simply relocated — and the company's advantage stopped compounding at precisely the point where the expensive part of drug development begins. Cheaper candidates produced more parallel programmes and therefore more capital required, not less.

Where it stands

Value in this stream has concentrated in trial-cost compression — site networks, recruitment, decentralised monitoring, real-world evidence that can support a label — rather than in candidate volume. The platforms that partnered early for the evidence step are the ones still setting terms.

Candidate cost reduction

~10x

Trial cost and duration change

~0

Where value moved

evidence generation

Cheap candidates do not shorten trials. Underwrite the evidence step, because that is the business and that is where the cost is.

Setup

Peer-reviewed accuracy above the human baseline on a retrospective dataset, sold into hospital systems with an annual budget cycle, a compliance function, a clinical governance committee and an existing PACS vendor with contractual leverage over integration.

What happened

Accuracy did not clear procurement. Two years of enthusiastic pilots produced no system-wide contract, because no committee had a line item for accuracy and every one of them had a line item for staffing and throughput. The deal signed only after the vendor produced audited numbers showing a specific department reading more studies per shift with the same headcount.

Where it stands

Sales now open with the budget line the product reduces and bring the accuracy data as supporting evidence rather than as the pitch. The cycle has shortened by roughly half and the pilots convert, because the pilot is now designed to generate the throughput evidence procurement needs.

Pilots before first system contract

2 years

What unlocked it

throughput evidence

Sales cycle since

~50% shorter

The buyer is a budget cycle, not a clinician. Accuracy is table stakes; documented cost, throughput or risk reduction is the sale.